CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
CEL-SCI Corporation Issues Letter to Shareholders
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility
EMA Grants CEL-SCI a Waiver of Strict Pediatric Requirements
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments.
CEL-SCI Releases Detailing Phase 3 & its Plans to Seek Regulatory Approvals